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Objectives: Perioperative bleeding sometimes results in severe consequence. An 
understanding of hemostasis approaches is crucial in managing the operations. This 
review aims to show the development of hemostasis in surgery around the world 
including China. MethOds: Literature in PUBMED was searched between 2009 
and 2014; search terms included hemostasis and surgery; filters included human, 
English and clinical trials. A similar search was done in Chinese CNKI database. 
Searching results were carefully reviewed and studies compatible with our inclu-
sion criteria were then selected. Results: From an initial search which yielded 
99 references in PUBMED and 50 references in CNKI, 54 articles in PUBMED and 16 
articles in CNKI were included in the review. Operations in 11 subjects were involved 
in these articles. We found that conventional hemostasis (classic technique of tying 
and knots, resorbable ligature) was gradually replaced by novel techniques such 
as bipolar tissue sealant device, ultrasound scalpel, hempclips, blue-violet light 
emitting diode irradiation, Ankaferd Blood Stopper, etc. Fibrin sealant, collagen 
hemostat and chitosan gel had important roles to be supplement. Certain drugs 
(tranexamic acid, Fibrinogen concentrate, hemocoagulase, etc) used perioperatively 
could be efficient too. On the other hand, some new techniques (vascular clips) 
failed to show significant benefits in some subjects (thyroid surgery). Furthermore, 
some techniques (bipolar coagulation) might affect the postoperative function of 
certain organs (ovary). While some techniques (harmonic scalpel) could save the 
whole cost in hospital, most could not. Information in China was similar with the 
world. cOnclusiOns: Some of the novel hemostasis approaches in surgery could 
decrease blood loss perioperatively as well as reduce operative time, hospital stay, 
the rate of complications and the whole cost. However, some shortcomings still exist 
and more correlative researches should be performed in the future.
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Objectives: Pharmacoeconomics is a newly developed discipline in China. 
Economic assessment is increasingly used as supportive evidence driving pricing 
and reimbursement decisions. Nevertheless, guidelines are necessary to homog-
enise their practice and promote their use. Among the different guidelines that 
have been published, two published in 2006 and in 2011 significantly support the 
implementation of pharmacoeconomics in China. Since multinational pharma-
ceutical companies are increasingly present in the Chinese market, this tends to 
increase the spread of such publications. This paper aims to quantify the impact 
of the introduction of guidelines as incentives to publish international articles in 
China. MethOds: A literature review was undertaken using the Pubmed data-
base. Keywords used in the search strategy were: ‘China’, ‘Pharmacoeconomics’, 
‘Economic Evaluation’, ‘Cost-Effectiveness’, ‘Cost of Illness’, ‘Cost-Benefit’, ‘Cost-
Utility’, ‘Cost-Minimization’ and ‘Budget Impact’. We used a timeframe of ten 
years before the first pharmacoeconomic guideline to present. This corresponds to 
01/01/1996 to 14/03/2014. In order to take into consideration only international publi-
cations, only English papers were selected. A final screening was performed to select 
the articles directly related to pharmacoeconomics and only in China. Results: 
272 articles were found with the primary search strategy and 99 were selected using 
the final critera. On average, 1 paper was published every year until 2006 while 8 
were published between 2006 and 2010, and 16 after 2010. The publications’ pace 
increases exponentially from 2011 to finally reach 19 publications in 2013. In the 
first ten weeks of 2014, 9 articles are already particularly intense, which can be 
interpreted as real trend. cOnclusiOns: This study reveals a correlation between 
pharmacoeconomic guidelines and volume of publications. Even if the place of 
this new discipline remains minor because of the initial level of submission, sig-
nificant efforts are undertaken to submit and use pharmacoeconomic studies as 
fully-fledged, leading to pricing and reimbursement decisions.
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Objectives: It has been shown in literatures that full-time intensivists improve the 
quality of patient care and reduce medical resource utilization. The study compares 
the quality of care in Respiratory Care Center (RCC) staffed by full-time intensiv-
ists (no outpatient clinics), part-time responsible chest physicians (with duties in 
outpatient, inpatient, and RCC) and full-time responsible chest physicians (with at 
most 3 half-day outpatient clinics per week besides WCC) and predicts risk factors 
for mortality and weaning rates in RCC patients. MethOds: Retrospective data 
were collected and analyzed from all RCC patients in a medical center cared for 
by full-time intensivists from 2004 to 2005, part-time responsible chest physicians 
from 2008 to 2009, and full-time responsible chest physicians from 2011 to 2012 
to determine whether there were differences in the quality of care and predict 
risk factors for mortality and weaning in RCC patients. Results: There were 2,757 
patients in the study with an average age of 69 years, APACHE II scores of 16.68, mor-
tality of 23.90%, weaning rates of 50.68% and complication rate of 40.74%. Patients 
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Objectives: As medical representative’s job involves travelling, waiting, stress 
due to targets and extended work hours in the field, their health related qual-
ity of life may be compromised. There are no studies reporting health related 
quality of life, an exploratory study was done to understand factors influencing 
health related quality of life. MethOds: In this exploratory study a pilot tested 
questionnaire was used to collect information regarding medical representatives’ 
characteristics, demographics, work and life habits. For health related quality of 
life measurement both descriptive and visual analogue score of EQ 5D 5L ques-
tionnaire were used. The data collected was analyzed using SPSS 16.0.0. The test 
of significance was done by using Kruskal-Wallis test. Results: This is a part 
of large group study which is underway to record health related quality of life 
among medical representatives, the results presented here are of 150 medical 
representatives. Mean age of the population studied was 27.58±4.6, 25% having 
more than 4 family dependents and 53 % were science graduates. 59.3% worked for 
more than 8 hours per day. 45.3% were not involved in doing any physical activity. 
Mean BMI was 23.52±3.45 and VAS score was 84.46±12.59. There was significant 
difference of VAS score among the groups involved in doing and not doing any 
physical activity (p< 0.001). cOnclusiOns: Even though the population studied 
was young, involvement in physical activity makes a difference in their health 
related quality of life.
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Objectives: The perception and the knowledge of health care at the end of life is 
the fundamental key to prevent an aggressive and useless therapy to patients at 
this stage of life and even more, which may cause more suffering to patients and 
burden the health care expenditures. This study aims to point out the possible 
impact of unawareness in palliative care under the pharmacotherapeutic aspect 
to help subsidize the development of improvement programs in this new medi-
cal area. MethOds: This study was conducted in 2013, in a mid-sized public and 
teaching general hospital, located in Sao Paulo, Brazil. It was based on direct critical 
assessment of medical prescription sheets of 15 patients classified as terminally ill-
ness and should receive palliative care Results: Approximately half of the patients 
were admitted to the intensive care unit, 66% were medical patients and 33% are 
surgical, almost of them all were adult patients (93.3%). All of them received non-
opioid analgesics and antipyretics; 80% received antacids and anticoagulants drugs; 
66.6% received hypoglycemic drugs; 53.3% received antimicrobial and antihyper-
tensive drugs; 46.6% received vasoactive drugs; 40% received opioids, cardiotonic 
drugs and statin therapy. And 33% patients received antiplatelet drugs and blood 
products; 26.6% received muscle relaxant drugs, and only 20% received corticos-
teroids cOnclusiOns: As we found only few prescriptions asking for opioids and 
benzodiazepines, but there were more frequently to vasoactive drugs, we can say 
that many therapeutic resources are still wrongly applied to patients classified as 
terminals. And as well as they receiving untimely and costly treatments, unfortu-
nately these efforts do not bring true compatible with their benefit needs, just is 
physical pain relief and anxiety reduction. Thus, it is essential to promote efforts 
to disseminate and clarify what is palliative care and how to provide more rational 
and humane care to these patients.
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Objectives: Primary Objective: – To study prescription pattern of antibiotics as 
prophylactic and in post surgery infection. Secondary objective: – To determine 
antibiotic sensitivity pattern in bacterial isolate MethOds: The study was a pro-
spective study for a period of four month from Jan-May 2013, Prescriptions and 
patient records files are reviewed and analyzed. Prescription pattern and antibiotic 
sensitivity was also evaluated. Results: Total 154 patients were included in our 
study from these 59% were male (n= 91) and 41% were female (n= 63). Total 19 dif-
ferent antibiotics were prescribe in general surgery in which Amikacin (n= 106, 
69%), ceftriaxone (n= 104, 67%) and metronidazole (n= 72, 47%) are most com-
monly prescribed antibiotics. Most of the patient had undergone hernioplasty 
surgery (n= 33, 22%) followed by Incision & Drainage (n= 23, 15%), debridement 
(n= 21, 14%), Appendicectomy (n= 16, 10%). Pus swab culture (44%) are done most 
frequently followed by wound culture (n= 13, 24%), urine culture (n= 9, 17%) in 
culture and sensitivity test. Most common isolate were klebsiellia sp. (n= 12, 31%), 
followed by S. aureas (n= 9, 21), E. coli (n= 8, 19%) which are resistant to ampicillin, 
amoxicillin, carbenicillin, ceftriaxone, cefuroxime, ceftazidime and cefotaxime 
and sensitive to levofloxacine, gatifloxacine and amikacin. cOnclusiOns: There 
was high tendency to prescribe the 3rd generation cephalosporins. Physicians pre-
scribed ceftriaxone antibiotic as prophylaxis for hernioplasty, appendectomy and 
Lap. Cholecytectomy. Most of the patients admitted to surgery unit had received 
antibiotic without regard to Culture Sensitivity report and standard guidelines. 
E. coli isolates were found to be 100% resistant to all penicillins, 3rd generation 
cephalosporins, cotrimoxazole and amoxiclav and Klebsella species were found 
to be 100% resistant to ampicillin.
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opportunities to grow. On the other side, the fierce competition among biosimilars 
with the same reference biologics and upcoming MNC’s next generation antibody 
therapies are also putting a threat to biosimilar market as a whole. cOnclusiOns: 
If pathways cannot be tailor-made for biosimilars in the future, thus hinders the fast 
launch of biosimilar products in China, population may not be able to enjoy more 
cost effective treatments and government may also lose the chance to benefit from 
the saving of the total health care expenditure.
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Objectives: There are challenges to assess the current situation of health care 
organizations’ waste management by the level and to formulate methods for fur-
ther improvement. Thus, purpose of this assessment study was to formulate ref-
erence about methods to improve current situation of health care organizations’ 
waste management. MethOds: Study was done by the descriptive method among 
39 health care organizations using study forms, as questionnaires, checklist and 
tests. Results: In Ulaanbaatar waste disposal company is 100% responsible for 
hazardous waste of health care organizations, but 50% of domestic waste are taken 
care by hospitals themselves. However, in rural areas 48.7- 64% of hospitals and 
57.1% of health care centers are responsible for both their domestic and hazardous 
waste. 50% of hospitals drain the liquid waste into main sewage and liquid waste 
from laboratory are drained into central sewage after disinfection. Waste manage-
ment team works in 66.7% of hospitals, and nurses and dry-nurses are responsible 
in collecting of waste in 97.4% of hospitals. The team consists of 1-3 people in 
50% of hospitals, 4-6 people in 39.5% of hospitals but more people in tertiary level 
hospitals. cOnclusiOns: Legal documents about waste management of health 
care organizations are approved; most secondary and tertiary level health care 
organizations have workers responsible for waste. They have developed plans to 
improve the “Waste management” and installed waste registration system. Despite 
setting up the temporary storages at hospitals and health care centers, they still 
need improvement. Although any equipment with mercury has been prohibited 
to use in health care organizations, 50% of hospitals are still using and it has been 
difficult to collect, transport and dispose mercury containing waste.
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Objectives: This study is designed to review and to compare the concept and con-
tent of market access in both western and Chinese pharmaceutical environments, 
and further endeavor to clarify the responsibilities of each stakeholder in China to 
help providing better drug accessibility and affordability for the people. MethOds: 
A literature review was undertaken to understand comprehensively the current 
market access protocols in mature markets as well as in China. Industry interviews, 
consulting surveys and data analysis were also conducted to collect first-hand data 
for comparison. Results: Unlike developed countries, where drug market access 
includes reimbursement and lots of patient access schemes, the market access of 
pharmaceuticals in China has a much broader scope, ranging from pricing, reim-
bursement, tendering, to hospital listing, etc, which indicates drug market access 
in China is a highly fragmented process and involves a lot of different govern-
ment departments. The centralized government management style, a historical 
consequence of the transformation from planned economy to market economy, 
is most attributable to this phenomenon. As a result, civil society, such as NGOs 
and academic institutions are relatively weaker compared to western countries, 
and they are not able to take intrinsically influential roles during market access 
decision-making process. This further leads to a high administration-oriented and 
low market-oriented drug market access present circumstance. Consequently, the 
timeline of drug market access in China is much longer than that of the mature 
market. cOnclusiOns: The definition of market access in China needs to be re-
defined and global perspectives shall be incorporated. A re-structured concept will 
better serve China’s changing environment.
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Objectives: Even the Ministry of Health is taking its attention to improve quality 
and safety of medical services, developing and implementing relevant policy and 
directions, quantity of complaints and occupational mistakes coming from citizens 
for medical services are still not going down. Therefore it is very necessary for every 
health organizations to analyze the situation. MethOds: To study processes for evi-
dences and requirements of quality, information is collected by quantitave method 
and the cross sectional survey form was used. Results: On the service standard 
surveys taken from medical staffs, 56.6% in I level hospitals, 50.0% in II level hos-
pitals and 73.3% in III level hospitals are replied as they follow certain standards 
for their services. But respondents replied as 47.4% of the standards for medical 
services, which is the most percent, are not incompatible for wards. When summa-
rizing the results, we can say it is not clear what service standards the medical staffs 
cared for by the full-time intensivists had a shorter RCC and ventilator days, lower 
expenses and RCC transfer rates (p < 0.001), and higher weaning and complication 
rates (p < 0.05) than those cared for by the part-time and full-time responsible chest 
physicians. Risk factors for mortality variables including APACHE II, transfer to the 
ICU, RCC length of stays, and albumin level. APACHE II, types of physicians staffed, 
transfer to the ICU, RCC length of stays, and Creatinine were the risk factors affecting 
weaning rates in the RCC patients. cOnclusiOns: There were differences in the 
overall use of health care resources and weaning rates among the patients cared 
for by full-time intensivitsts, part-time responsible chest physicians, and full-time 
responsible chest physicians but no difference in adjusting mortality.
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Objectives: This study focuses on the regulations made by government of India for 
Nutraceuticals labeling requirements and the need of change in the monitoring system in 
the same our objectives for the study were: 1. to understand labeling regulations of 
Nutraceuticals in India. 2. To study labels of selected Nutraceutical products from 
health care market. MethOds: For objective first we have studied the regulations 
made by FDA of India regarding Nutraceuticals labeling requirement, for which we 
have used secondary data collection method. For second objective we have collected 
30 samples randomly from Nutraceutical segments from local Pharmacies and stud-
ied the labels carefully. Results: The follow-up by Nutrceuticals manufacturer to 
labeling regulations found very moderate in our study. We found that regulations 
about list of ingredients, nutritional value, declaration regarding veg non-veg, dec-
laration regarding food additives and other crucial parts of label are poorly followed 
by Nutraceutical Manufacturer in India. cOnclusiOns: As we have studied the 
regulations regarding labeling of Nutraceuticals, we found that this regulations are 
sufficient and appropriate. Again through this research work we come to make this 
conclusion that Nutraceutical manufacturer/importer in India are not that much 
serious regarding labeling which is threatening in some aspects so they used to 
make mistakes in labeling knowingly or unknowingly.
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Objectives: To develop a method of setting a Drug Price Reference Index (DPRI) in 
the Philippines to ensure good value for money in the procurement and reimburse-
ment of essential medicines. MethOds: A database of prevailing drug procurement 
prices was created from actual purchase orders submitted in 2012 by government 
procuring entities in the Philippines. The database includes information on the 
unit cost, volumes of procurement, source/supplier/manufacturer, brand, mode of 
procurement and location of the hospital for each formulation and strength of all 
drugs in the National Formulary. Univariate regression analyses were performed 
for commonly sourced essential drugs exploring possible determinants of drug 
costs, which include quantities procured and hospital bed capacity. Further cost-
comparisons were made for other potential determinants such as mode of procure-
ment, supplier/manufacturer and distance of distribution. Results: Price data was 
analyzed for 20 drug products with the highest share of procurement in terms of 
volume and value. Extreme wide variations in unit costs were consistently observed 
for all drugs analyzed. The price differentials, i. e. high/low ratio, was found to be up 
to 60 times when comparing the highest to the lowest priced drugs. The variations 
in prices were not associated by volumes procured, distance of distribution and 
hospital bed capacity. Suppliers were also observed to charge different prices for 
the same brands to different public hospitals, indicating information asymmetry 
on reasonable prices of drugs. cOnclusiOns: Based on the observed wide varia-
tions in drug procurement prices in the Philippines, setting the DPRI at the median 
value for most drugs was found to be an appropriate method to set ceiling prices 
for public sector procurement. For monopolized pharmaceutical products, other 
methods may be more appropriate such as value-based pricing, price negotiations 
and external reference pricing to relevant countries.
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Objectives: This study aims to review released policies with regards to biosimilar 
products in China, and further understand the external environment that shapes 
the biosimilar market. MethOds: A literature review on laws, regulations and 
policies released by key government stakeholders and other additional docu-
ments was performed to fully capture the policy environment for biosimilars in 
China. Results: Multiple policies have been issued at central government level to 
encourage the development of biologics industry in China. Nevertheless, rather than 
in favor of accelerating market access for biologics, those policies are more R&D 
and manufacturing quality control focused. There is no clear regulatory pathway 
for biosimilars in China to date. Due to the lack of clear standard for biosimilars to 
prove their bioequivalence to the originators, biosimilars are treated as new drugs 
at each stage of market access, resulting in a delay of getting approval in China 
market. Currently, local biosimilar developers are actively building their capabilities 
in innovative biologics such as monoclonal antibodies, while MNC players are con-
tinuing to bring in new molecules. As original products’ patent expiry peak period 
is coming, biosimilars, whose prices are relatively affordable, have potential huge 
